In a move that has taken the biotech world by surprise, AI‑powered research startup Lila Sciences has just crossed the $1.3 billion mark in valuation. The jump comes after the company secured a fresh investment from tech giant Nvidia, which is looking to expand its reach into drug‑discovery applications.
Lila Sciences, founded in 2019, builds AI tools that help scientists design molecules and predict how new drugs will behave. Its platform uses large language models to flatten the research timeline, cutting down the months it normally takes to bring a new compound into clinical trials. The company has already won praise from several pharma firms eager to speed up their development pipelines.
Last month, Lila Sciences announced a new funding round that saw Nvidia commit $50 million, joining earlier investors such as Andreessen Horowitz and Illumina. The partnership is significant because Nvidia not only provides the chips that power Lila’s models but also brings expertise in scaling AI workloads for scientific research.
Earlier this year, the startup raised $138 million from a portfolio of investors, propelling its valuation to $1.3 billion. That figure places Lila Sciences among the top AI‑driven biotech firms in the U.S., and signals that large tech companies are willing to bankroll AI solutions that could transform drug development.
“The partnership with Nvidia gives us the computational muscle we need to push the boundaries of AI in biology,” said Lila’s CEO, Li Ma. “We’re excited to work with a company that thrives on solving complex problems, especially in the life sciences.”
Pharmaceutical companies are watching closely. Lila’s platform can potentially reduce the cost of discovering new medicines while speeding up the path to testing. Analysts say that if Lila can go beyond pilot projects and deliver commercial results, the valuation could rise even further.
So while Lila Sciences may have started as a niche AI lab, its new backing from Nvidia and a valuation of $1.3 billion hint at a larger shift. Investors and pharma executives alike are keeping a close eye on how this partnership will shape the future of drug discovery.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
